Article Text

Download PDFPDF
Original research
Updated classification with spinal dysraphism and treatment outcomes of arteriovenous shunts below conus: a retrospective cohort study
  1. Yu-xiang Fan1,2,
  2. Cheng-bin Yang1,2,
  3. Jing-wei Li1,2,
  4. Jia-chen Wang3,
  5. Peng Hu1,2,
  6. Ming Ye1,2,
  7. Gui-lin Li1,2,
  8. Li-song Bian4,
  9. Peng Zhang1,2,
  10. Yong-jie Ma1,2,
  11. Hong-qi Zhang1,2
  1. 1Department of Neurosurgery, Xuanwu Hospital Capital Medical University, Beijing, China
  2. 2China International Neurological Institute, Beijing, China
  3. 3Department of Neuro-oncology, Beijing Tiantan Hospital, Beijing, China
  4. 4Department of Neurosurgery, Beijing Haidian Hospital, Beijing, China
  1. Correspondence to Dr Hong-qi Zhang; xwzhanghq{at}163.com; Dr Yong-jie Ma; mayongjiedoctor{at}sina.com

Abstract

Background Arteriovenous shunts below conus medullaris (AVS-BC) are understudied, particularly those associated with spinal dysraphism. This study aimed to refine the classification and management of AVS-BC.

Methods A retrospective analysis of patients with AVS-BC from two centers over two decades was performed, focusing on clinical presentations, angioarchitecture, and treatment outcomes. AVS-BC was classified into eight subtypes based on angioarchitecture, dural relation, and spinal dysraphism presence. Treatment efficacy was evaluated using changes in the modified Aminoff and Logue’s Scale and the modified Denis Pain and Numbness Scale.

Results The cohort included 140 patients (85.0% male) with a median onset age of 54 years (IQR 47–62). Spinal dural arteriovenous fistula was the most prevalent subtype (32.1%). AVS-lipoma (58.8%) and AVS with spina bifida/meningocele (75.0%) were mainly located in S3–S5, while others were above S2 (p<0.001). Most AVS-BCs were supplied by the internal iliac artery (37.1%) and drained intradurally (96.4%). Venous lakes were common in spinal epidural arteriovenous fistula (88.2%) and paravertebral arteriovenous fistula (100.0%). Larger drainage veins (>2.0 mm) were found in paravertebral arteriovenous fistula (PVAVF) (50.0%) and AVS with spina bifida/meningocele (AVS-SBD) (50.0%) (p=0.012). Embolization was the preferred treatment (50.7%), achieving a 97.1% anatomical cure rate. Despite functional improvements, 25% experienced deterioration during a median follow-up of 47 months (IQR 20–113).

Conclusions The refined AVS-BC classification revealed significant angioarchitectural variations. Tailored treatment strategies, especially embolization, resulted in high anatomical cure rates, though post-treatment deterioration warrants further investigation.

  • Angiography
  • Vascular Malformation
  • Lumbosacral
  • Fistula

Data availability statement

Data are available upon reasonable request. The data that supported the findings of this study are available from the corresponding author upon reasonable request.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

Data are available upon reasonable request. The data that supported the findings of this study are available from the corresponding author upon reasonable request.

View Full Text

Footnotes

  • Y-xF and C-bY contributed equally.

  • Contributors HZ and YF conceptualized the study; YF drafted the initial manuscript; YF, CY, JL, JW, PH, MY, GL, LB, YM, and PZ conducted data collection and analysis. YF, CY, JL, and JW prepared figures, PH, PZ, YM, and HZ undertook comprehensive revisions and editing. HZ and YM acquired funding. All authors have reviewed and endorsed the manuscript. HZ is the guarantor.

  • Funding This study was funded by the National Natural Science Foundation of China (No 82101460 and 82220108010).

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Linked Articles